A very large study of Copaxone for primary progressive MS showed no meaningful benefit of treatment compared to placebo. Smaller studies of Copaxone for progressive MS that were done prior to its approval for relapsing MS also failed to show any meaningful benefit of Copaxone in this phase of the disease.
Rip Kinkel, MD
PLEASE NOTE: This information/opinions on this site should be used as an information source only. This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.